{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.1","upperLimit":"4.5","value":"-1.8"},{"groupId":"OG001","lowerLimit":"-4.7","upperLimit":"6.9","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"At Day 64"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.1","upperLimit":"7.3","value":"1.1"},{"groupId":"OG001","lowerLimit":"-3.3","upperLimit":"8.0","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"At Day 134"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100, where 0 is the worst health you can imagine and 100 is the best health you can imagine.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG000","title":"Xevinapant +IMRT"},{"description":"Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle in combination with with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of placebo matched to Xevinapant from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG001","title":"Placebo +IMRT"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here,\"Overall Number of Participants Analyzed\" signifies the participants who were evaluable for this outcome measure and \"number analysed\" signifies participants at the specific categories.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 64 and End of treatment (Day 134)","title":"Change From Baseline in EuroQOL 5 Dimension 5 Level Health-Related Quality of Life Measure Visual Analog Scale Score (EQ-5D-5L VAS)","type":"SECONDARY","unitOfMeasure":"score on a scale"}